Is the New Menopause HRT Heart Safety Study Convincing?

The headline finding is straightforward: in a study following more than 52,000 women for 12 years, modern hormone replacement therapy did not increase the risk of heart attack, stroke, blood clots, or early death. Women who started HRT during midlife to manage symptoms like hot flashes had cardiovascular outcomes that were, in the researchers' words, remarkably similar to women who didn't take hormones.

That matters because fear of heart risk is one of the most common reasons women decline hormone therapy, and why some clinicians hesitate to prescribe it. The lead researchers behind the work, published in JAMA Internal Medicine, framed this as reassurance specifically for women managing vasomotor symptoms with currently available formulations, not a blanket endorsement for every possible use of hormones after menopause.

The distinction between absolute and relative risk matters here. Even studies that show elevated relative risk often involve small absolute numbers of additional events. This study's main achievement is showing no meaningful gap between the two groups at all, on either measure, across a 12-year window.

The first limitation is design. This is observational research, not a randomized controlled trial like the Women's Health Initiative. Observational studies can show strong associations, but they can't fully rule out that healthier women were simply more likely to be prescribed hormones in the first place, a problem researchers call selection bias.

The second limitation is timing. The women in this study generally started HRT during midlife, close to the onset of menopause. Decades of research, including reanalysis of the original WHI data, show that starting hormone therapy soon after menopause carries a very different risk profile than starting it ten or fifteen years later.

Some data even suggest a reduced cardiovascular risk for women who start early, particularly Black women and women with more severe symptoms, while risk tends to climb for women who start later or who already carry elevated cardiovascular risk. The third limitation is formulation. 'Hormone therapy' is not one drug.

Estrogen-only therapy, combined estrogen-progestogen therapy, patches, pills, and gels all behave differently in the body, and the study's reassurance applies to the modern formulations it actually tested, not to every hormone product on the market. Testosterone therapy, a separate and much less-researched category, showed the opposite signal: research presented at the 2026 Menopause Society meeting linked it to higher rates of heart attack and stroke in postmenopausal women.

Taken together, this study doesn't prove hormone therapy is safe for every woman at every stage. It shows that, for women who fit its profile, one of the biggest fears keeping them from treatment may not be justified.

If you're close to menopause onset and considering hormone therapy for symptom relief, this study adds meaningfully to the case that modern formulations don't carry the heart risk many people still associate with hormone therapy from the WHI era two decades ago. If you're many years past menopause, or you carry independent cardiovascular risk factors, this data doesn't speak directly to your situation.

Guidance from cardiology and menopause specialists, including reviews referencing the American College of Cardiology's Cardiovascular Disease in Women Committee, continues to recommend caution for women with a high 10-year atherosclerotic cardiovascular disease risk, regardless of how long ago menopause started. And if testosterone is part of the conversation, treat it as a separate decision entirely.

The cardiovascular signal there is newer, smaller, and points in the opposite direction from the reassurance seen with standard estrogen and combined therapies.